
Aclarion Inc (ACON) Stock Forecast & Price Target
Aclarion Inc (ACON) Analyst Ratings
Bulls say
Aclarion is a healthcare technology company with a positive outlook as it gains traction in the market for its Nociscan product, which provides critical insights into the location of a patient's low back pain, giving physicians clarity to optimize treatment strategies. With commercial agreements, increased marketing efforts, and an expanding share count, the company is investing in sales, R&D, and IR to drive future growth. While risks exist, such as slower enrollment in clinical trials, the company's strong cash position and potential market opportunity make it a promising investment with a 12-month price target of $7.50.
Bears say
Aclarion is facing challenges with its CLARITY trial, with initial data analysis and disclosure of early interim results delayed until Q4 2026. Additionally, while the company has a healthy cash runway, they also authorized a share-repurchase program, suggesting potential concerns about their current positioning and valuation. The delay in trial data and mixed signals about financial confidence could indicate underlying issues with the effectiveness and potential market success of Nociscan.
This aggregate rating is based on analysts' research of Aclarion Inc and is not a guaranteed prediction by Public.com or investment advice.
Aclarion Inc (ACON) Analyst Forecast & Price Prediction
Start investing in Aclarion Inc (ACON)
Order type
Buy in
Order amount
Est. shares
0 shares